Bioluminescent Approaches for Measuring Tumor Growth in a Mouse Model of Neurofibromatosis

被引：9

作者：

Hawes, Jessica J. ^{[1
]}

Reilly, Karlyne M. ^{[1
]}

机构：

[1] NCI, Mouse Canc Genet Program, Ft Detrick, MD 21702 USA

来源：

TOXICOLOGIC PATHOLOGY | 2010年 / 38卷 / 01期

基金：

美国国家卫生研究院;

关键词：

neurofibromatosis; astrocytoma; glioblastoma; malignant peripheral nerve sheath tumor; mouse models of cancer; bioluminescence; NERVE SHEATH TUMORS; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GLIOBLASTOMA-MULTIFORME; CELL-PROLIFERATION; IN-VIVO; NF1; TYPE-1; GENE; MICE; GLIOMAS;

D O I：

10.1177/0192623309357075

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Neurofibomatosis (NF1) patients arc susceptible to. multiple tumors of the nervous system including neurofibromas. optic glioma, malignant peripheral nerve sheath tumors(MPNSTs), and astrocytoma. The Nf1+/-; Trp53+/- (NPcis) mouse model of NF1 spontaneously develops astrocytoma and MPNSTs that Eire very similar to human NF1 tumors. To use this model for. testing potential therapeutics, we have developed systems that take advantage of bioluminescent reporters of tumor growth. We have generated E2F1 promoter-driven luciferase (ELUX) reporter mice to detect proliferating tumors in NPcis mice in vivo using bioluminescence. The power of this system is that it enables looking at tumor evolution and detecting spontaneous tumors at early stages of development as they evolve within their natural haploinsufficient microenvironment. This system can be used to identify tumors at different stages of tumorigenesis Mid to examine where spontaneous NF1 tumors initiate. The ability to rapidly screen multiple animals at a time increases the potential for use of this model in preclinical trials. This model will be valuable for the characterization of spontaneous NF1 tumors and will be important for studying the treatment and prevention of NF1 tumors in vivo.

引用

页码：123 / 130

页数：8

共 36 条

[1]

Bajenaru ML, 2003, CANCER RES, V63, P8573

[2]

Becher O. J., 2006, CANCER RES, V66, P3358

[3] Genetically engineered models have advantages over xenografts for preclinical studies [J].

Becher, OJ ;

Holland, EC .

CANCER RESEARCH, 2006, 66 (07) :3355-3358

[4] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[5] Mouse models of tumor development in neurofibromatosis type 1 [J].

Cichowski, K ;

Shih, TS ;

Schmitt, E ;

Santiago, S ;

Reilly, K ;

McLaughlin, ME ;

Bronson, RT ;

Jacks, T .

SCIENCE, 1999, 286 (5447) :2172-2176

[6] Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth [J].

Daginakatte, Girish C. ;

Gutmann, David H. .

HUMAN MOLECULAR GENETICS, 2007, 16 (09) :1098-1112

[7] Malignant peripheral nerve sheath tumours in neurofibromatosis 1 [J].

Evans, DGR ;

Baser, ME ;

McGaughran, J ;

Sharif, S ;

Howard, E ;

Moran, A .

JOURNAL OF MEDICAL GENETICS, 2002, 39 (05) :311-314

[8] Models for assessment of angiogenesis in gliomas [J].

Goldbrunner, RH ;

Wagner, S ;

Roosen, K ;

Tonn, JC .

JOURNAL OF NEURO-ONCOLOGY, 2000, 50 (1-2) :53-62

[9] p53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective [J].

Harris, CC .

CARCINOGENESIS, 1996, 17 (06) :1187-1198

[10] Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds [J].

Hawes, Jessica J. ;

Nerva, John D. ;

Reilly, Karlyne M. .

JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (08) :795-803

← 1 2 3 4 →